0
0

Emergency Use Transparency Act

12/30/2022, 3:34 AM

Congressional Summary of S 3394

Emergency Use Transparency Act

This bill expands existing statutory provisions requiring the Food and Drug Administration (FDA) to publish notices of authorizations, terminations, or revocations of emergency use authorizations for medical products.

Specifically, the bill requires the FDA to publish such notices on its website. The bill also allows the FDA's disclosures to include a summary of data or information from additional types of submissions.

Current Status of Bill S 3394

Bill S 3394 is currently in the status of Bill Introduced since December 14, 2021. Bill S 3394 was introduced during Congress 117 and was introduced to the Senate on December 14, 2021.  Bill S 3394's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of December 14, 2021

Bipartisan Support of Bill S 3394

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
2
Democrat Cosponsors
0
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 3394

Primary Policy Focus

Health

Potential Impact Areas

- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Emergency medical services and trauma care
- Food and Drug Administration (FDA)
- Government information and archives
- Health technology, devices, supplies

Alternate Title(s) of Bill S 3394

Emergency Use Transparency Act
Emergency Use Transparency Act
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to emergency use authorization transparency.

Comments